Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.

Kushner BH, LaQuaglia MP, Modak S, Wolden SL, Basu EM, Roberts SS, Kramer K, Yataghene K, Cheung IY, Cheung NV.

Oncotarget. 2017 Aug 24;8(56):95293-95302. doi: 10.18632/oncotarget.20513. eCollection 2017 Nov 10.

2.

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.

Ladenstein R, Lambert B, Pötschger U, Castellani MR, Lewington V, Bar-Sever Z, Oudoux A, Śliwińska A, Taborska K, Biassoni L, Yanik GA, Naranjo A, Parisi MT, Shulkin BL, Nadel H, Gelfand MJ, Matthay KK, Park JR, Kreissman SG, Valteau-Couanet D, Boubaker A.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):292-305. doi: 10.1007/s00259-017-3829-7. Epub 2017 Sep 23.

3.

Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.

Berthold F, Spix C, Kaatsch P, Lampert F.

Paediatr Drugs. 2017 Dec;19(6):577-593. doi: 10.1007/s40272-017-0251-3.

4.

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.

Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, Heller G, Cheung NK, Hsu KC.

J Clin Oncol. 2016 Jul 20;34(21):2443-51. doi: 10.1200/JCO.2015.64.9558. Epub 2016 Apr 11.

5.

Short-Interval Retreatment With Stereotactic Body Radiotherapy (SBRT) for Pediatric Neuroblastoma Resulting in Severe Myositis.

Taunk NK, Kushner B, Ibanez K, Wolden SL.

Pediatr Blood Cancer. 2016 Apr;63(4):731-3. doi: 10.1002/pbc.25863. Epub 2016 Jan 25.

6.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK.

Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.

7.

Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target.

Yco LP, Geerts D, Mocz G, Koster J, Bachmann AS.

BMC Cancer. 2015 Jun 21;15:477. doi: 10.1186/s12885-015-1447-y.

8.

Development and characterization of a human orthotopic neuroblastoma xenograft.

Stewart E, Shelat A, Bradley C, Chen X, Federico S, Thiagarajan S, Shirinifard A, Bahrami A, Pappo A, Qu C, Finkelstein D, Sablauer A, Dyer MA.

Dev Biol. 2015 Nov 15;407(2):344-55. doi: 10.1016/j.ydbio.2015.02.002. Epub 2015 Apr 9.

9.
10.

Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.

Cheung NK, Ostrovnaya I, Kuk D, Cheung IY.

J Clin Oncol. 2015 Mar 1;33(7):755-63. doi: 10.1200/JCO.2014.57.6777. Epub 2015 Jan 5.

11.

Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.

Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, Roberts SS, Cheung NK.

Cancer. 2014 Jul 1;120(13):2050-9. doi: 10.1002/cncr.28687. Epub 2014 Apr 1.

12.

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.

Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG.

Lancet Oncol. 2013 Sep;14(10):999-1008. doi: 10.1016/S1470-2045(13)70309-7. Epub 2013 Jul 25.

13.

Single-walled carbon nanotube-mediated small interfering RNA delivery for gastrin-releasing peptide receptor silencing in human neuroblastoma.

Qiao J, Hong T, Guo H, Xu YQ, Chung DH.

Methods Mol Biol. 2013;1026:137-47. doi: 10.1007/978-1-62703-468-5_11.

14.

Etoposide sensitizes neuroblastoma cells expressing caspase 8 to TRAIL.

Kim HR, Lee MW, Kim DS, Jo HY, Lee SH, Chueh HW, Jung HL, Yoo KH, Sung KW, Koo HH.

Cell Biol Int Rep (2010). 2012 Jun 21;19(1):e00017. doi: 10.1042/CBR20110008.

15.

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S.

J Clin Oncol. 2012 Sep 10;30(26):3264-70. doi: 10.1200/JCO.2011.41.3807. Epub 2012 Aug 6.

16.

Integrin-linked kinase regulates phosphatase and tensin homologue activity to promote tumorigenesis in neuroblastoma cells.

Taylor CJ, Qiao J, Colon NC, Schlegel C, Josifi E, Chung DH.

Surgery. 2011 Aug;150(2):162-8. doi: 10.1016/j.surg.2011.05.007. Epub 2011 Jun 29.

17.

Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?

Bellanti F, Kågedal B, Della Pasqua O.

Eur J Clin Pharmacol. 2011 May;67 Suppl 1:87-107. doi: 10.1007/s00228-010-0966-3. Epub 2011 Feb 2. Review.

18.

Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.

Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R, London WB, Yap JS, Kreissman SG.

Pediatr Blood Cancer. 2010 Apr;54(4):596-602. doi: 10.1002/pbc.22344.

19.

KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.

Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O'Reilly RJ, Cheung NK, Hsu KC.

Clin Cancer Res. 2009 Dec 1;15(23):7330-4. doi: 10.1158/1078-0432.CCR-09-1720. Epub 2009 Nov 24.

20.

Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.

Kushner BH, Cheung NK, Barker CA, Kramer K, Modak S, Yataghene K, Wolden SL.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1181-6. doi: 10.1016/j.ijrobp.2008.12.026. Epub 2009 May 8.

Supplemental Content

Support Center